221 related articles for article (PubMed ID: 23219766)
1. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?
Modena V; Bianchi G; Roccatello D
Autoimmun Rev; 2013 Jun; 12(8):835-8. PubMed ID: 23219766
[TBL] [Abstract][Full Text] [Related]
2. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
[TBL] [Abstract][Full Text] [Related]
3. Critical analysis of economic tools and economic measurement applied to rheumatoid arthritis.
Her M; Kavanaugh A
Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S107-11. PubMed ID: 23078839
[TBL] [Abstract][Full Text] [Related]
4. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
[TBL] [Abstract][Full Text] [Related]
5. Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey.
Hamuryudan V; Direskeneli H; Ertenli I; Inanc M; Karaaslan Y; Oksel F; Ozbek S; Pay S; Terzioglu E; Balkan Tezer D; Hacibedel B; Akkoc N
Clin Exp Rheumatol; 2016; 34(6):1033-1037. PubMed ID: 27749224
[TBL] [Abstract][Full Text] [Related]
6. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
[TBL] [Abstract][Full Text] [Related]
7. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept.
Neubauer AS; Minartz C; Herrmann KH; Baerwald CGO
Clin Exp Rheumatol; 2018; 36(3):448-454. PubMed ID: 29303709
[TBL] [Abstract][Full Text] [Related]
9. The costs of rheumatoid arthritis.
Allaire SH; Prashker MJ; Meenan RF
Pharmacoeconomics; 1994 Dec; 6(6):513-22. PubMed ID: 10155281
[TBL] [Abstract][Full Text] [Related]
10. The economics of treatment in early rheumatoid arthritis.
Bansback N; Marra CA; Finckh A; Anis A
Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):83-92. PubMed ID: 19233048
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Maetzel A; Strand V; Tugwell P; Wells G; Bombardier C
Arthritis Rheum; 2002 Dec; 47(6):655-61. PubMed ID: 12522841
[TBL] [Abstract][Full Text] [Related]
12. Direct medical costs associated with rheumatoid arthritis in Turkey: analysis from National Claims Database.
Baser O; Burkan A; Baser E; Koselerli R; Ertugay E; Altinbas A
Rheumatol Int; 2013 Oct; 33(10):2577-84. PubMed ID: 23708559
[TBL] [Abstract][Full Text] [Related]
13. Burden of rheumatoid arthritis from a societal perspective: A prevalence-based study on cost of this illness for patients in China.
Hu H; Luan L; Yang K; Li SC
Int J Rheum Dis; 2018 Aug; 21(8):1572-1580. PubMed ID: 28211251
[TBL] [Abstract][Full Text] [Related]
14. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany.
Gissel C; Götz G; Repp H
Z Rheumatol; 2016 Dec; 75(10):1006-1015. PubMed ID: 27080399
[TBL] [Abstract][Full Text] [Related]
16. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis.
Furneri G; Mantovani LG; Belisari A; Mosca M; Cristiani M; Bellelli S; Cortesi PA; Turchetti G
Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S72-84. PubMed ID: 23072761
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review.
van der Velde G; Pham B; Machado M; Ieraci L; Witteman W; Bombardier C; Krahn M
Arthritis Care Res (Hoboken); 2011 Jan; 63(1):65-78. PubMed ID: 20740606
[No Abstract] [Full Text] [Related]
18. Canadian estimates of health care utilization costs for rheumatoid arthritis patients with and without therapy with biologic agents.
Ohinmaa AE; Thanh NX; Barnabe C; Martin L; Russell AS; Barr SG; Maksymowych WP
Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1319-27. PubMed ID: 24470178
[TBL] [Abstract][Full Text] [Related]
19. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency.
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Pharmacoeconomics; 2005; 23(4):395-420. PubMed ID: 15853438
[TBL] [Abstract][Full Text] [Related]
20. [Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis].
Merkesdal S; Ruof J
Z Rheumatol; 2002; 61 Suppl 2():II/29-32. PubMed ID: 12491120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
